The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS™ (Linaclotide)

Thursday, November 01, 2012

Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS™ (Linaclotide)16:00 EDT Thursday, November 01, 2012 CAMBRIDGE, Mass. (Business Wire) -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will be hosting a webinar to provide an overview of how LINZESS will be reflected in Ironwood's quarterly income statements following its commercial availability in the U.S. Ironwood will co-commercialize the product in the U.S. through its collaboration with Forest Laboratories, Inc. The webinar will take place on Tuesday, November 6, 2012 at 12:00 p.m. Eastern Time. Individuals interested in participating in the webinar should visit the Investors section of Ironwood's website at; please log on at least 15 minutes prior to the start of the event to ensure adequate time for any software downloads that may be required. For listen-only participation, the webinar can also be accessed by dialing (866) 437-1772 (U.S. and Canada) or (973) 638-3229 (international) and use the conference ID number 45259150. A replay of the webinar will be available on Ironwood's website or via telephone starting November 6, 2012 at approximately 3:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 13, 2012. To listen to the replay by phone, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and use conference ID number 45259150. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit Ironwood Pharmaceuticals, Inc.Media RelationsLisa Buffington, 617-374-5103Vice President, Corporate Communicationslbuffington@ironwoodpharma.comorInvestor RelationsMeredith Kaya, 617-374-5082Associate Director, Investor